CUA Educational Content

Radiant Horizons: Exploring Real-World Applications and Potential of Radioligand Therapy

Recording from June 29, 2024

Speakers: Frédéric Pouliot & Urban Emmenegger

Objectives:

By participating in this learning program, healthcare providers can expect to gain an understanding of:

  • Current evidence supporting the use of radioligand therapy (RLT), how it fits within the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), and the importance of patient selection through PSMA PET imaging 
  • Logistical, clinical, and multidisciplinary considerations necessary for successfully implementing RLT programs, including coordination between nuclear medicine and oncology departments
  • The future of RLT, including clinical trials, emerging radiopharmaceuticals, and the potential for combination therapies, to better understand how RLT may evolve and expand its role in prostate cancer treatment
Start Quiz for Credits

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

This program has received financial support from Novartis in the form of an educational grant.

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy